
China’s state-backed developer Greenland Holdings is set to jointly invested over $1 billion in a San Francisco-based biotech industrial park …

Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …

The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …

Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …

MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s …
Ashfield, part of UDG Healthcare plc (LON: UDG), a global leader in providing outsourced healthcare services to pharmaceutical, device and …
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …

Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …
The US Food and Drug Administration (FDA) has issued a statement following the results of their investigation into the recent …

Chancellor Phillip Hammond has outlined a government commitment to guarantee EU funding for British research projects made before Britain leaves …

It’s Monday and we’re just getting back to it after a busy week in pharma. Unfortunately, it was mostly bad …

The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 …

Endo International has announced that, following discussions with the US Food and Drug Administration (FDA), it has decided to withdraw …

Novartis has sealed the deal with construction firm Jacobs Engineering group to expand production operations at its France Center of …